GlobeImmune, Inc is a biopharmaceutical company which recently filed with the SEC to go public, but have still not begun trading. The company was founded in 1995 as Ceres Pharmaceutical and changed its name to GlobeImmune in 2001. GlobeImmune has the ambitious goal of ending disease all over the world.
At the moment GlobeImmune is focusing its resources on Tarmogen, a way of stimulating cell-level immunity to cancer and other diseases. They produce their own products and partners with Celgene and Gilead Sciences to develop and distribute its drugs which fight cancer and infectious diseases.
GlobeImmune is headquartered in Louisville, Colorado, and filed their registration statement with the SEC on July 2, 2012. the number of shares or their price has not yet been determined, but they applied for their common stock to be listed on the NASDAQ Global Market using the symbol GBIM.
Wells Fargo Securities, LLC, and Piper Jaffray & Co will be the two book-running managers of the IPO. JMP Securities will be the co-manager.
Sorry, comments are closed for this post.